Related references
Note: Only part of the references are listed.Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
Seung Tae Kim et al.
GENOME MEDICINE (2021)
The Immunoscore: Colon Cancer and Beyond
Helen K. Angell et al.
CLINICAL CANCER RESEARCH (2020)
A pan-cancer analysis of HER2 index revealed transcriptional pattern for precise selection of HER2-targeted therapy
Ziteng Li et al.
EBIOMEDICINE (2020)
DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.
Raghav Sundar et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Perioperative FLOT: new standard for gastric cancer?
Yoon-Koo Kang et al.
LANCET (2019)
Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
R. Sundar et al.
ANNALS OF ONCOLOGY (2019)
RAD9A promotes metastatic phenotypes through transcriptional regulation of anterior gradient 2 (AGR2)
Constantinos G. Broustas et al.
CARCINOGENESIS (2019)
Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis
Jae-Ho Cheong et al.
LANCET ONCOLOGY (2018)
Genomic Analyses and Precision Oncology in Gastroesophageal Cancer : Forwards or Backwards?
Raghav Sundar et al.
CANCER DISCOVERY (2018)
A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).
Yasuhiro Kodera et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).
Yasuhide Yamada et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A Deep Neural Network Model using Random Forest to Extract Feature Representation for Gene Expression Data Classification
Yunchuan Kong et al.
SCIENTIFIC REPORTS (2018)
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept 3G Trial
Wei Peng Yong et al.
CLINICAL CANCER RESEARCH (2018)
Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma
Aditi Qamra et al.
CANCER DISCOVERY (2017)
FirebrowseR: an R client to the Broad Institute's Firehose Pipeline
Mario Deng et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2017)
Pharmacogenetic Analysis of the UK MRC(Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy
Elizabeth Smyth et al.
CLINICAL CANCER RESEARCH (2017)
Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line
Xiaoli Shi et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer
Yang Bai et al.
JOURNAL OF OVARIAN RESEARCH (2016)
The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update
Waseem Ahmad Siddiqui et al.
ARCHIVES OF TOXICOLOGY (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Second-line treatment of metastatic gastric cancer: Current options and future directions
Dheepak Kanagavel et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
E. Bajetta et al.
ANNALS OF ONCOLOGY (2014)
Robustness of Random Forest-based gene selection methods
Miron Bartosz Kursa
BMC BIOINFORMATICS (2014)
How Taxol/paclitaxel kills cancer cells
Beth A. Weaver
MOLECULAR BIOLOGY OF THE CELL (2014)
Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial
Akira Tsuburaya et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer
Tatiana Ivanova et al.
GUT (2013)
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
James W. Hodge et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy
Iain Beehuat Tan et al.
GASTROENTEROLOGY (2011)
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs
Charles Swanton et al.
CANCER CELL (2007)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Human homologue of S-pombe Rad9 interacts with BCL-2/BCL-x(L) and promotes apoptosis
K Komatsu et al.
NATURE CELL BIOLOGY (2000)
Share Paper
